KEYNOTE-522: Immune therapy and chemotherapy in patients with early triple negative breast cancer

Neoadjuvant pembrolizumab plus chemo followed by adjuvant pembrolizumab shows improvement in OSПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее

ÜÇLÜ NEGATİF (TRİPLE NEGATİVE) MEME KANSERİNDE YENİ TEDAVİLER VAR MI?Подробнее

Hope Rising: Immunotherapy in Early Breast CancerПодробнее

Virtual Case Library: Metastatic Triple-Negative Breast CancerПодробнее

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Tripl...Подробнее

Winship Grand Rounds: March 27, 2024 - Heather McArthur, MDПодробнее

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancerПодробнее

First Chemo Treatment for TNBC. Keynote 522Подробнее

Educational Sessions: "Immune therapy in the (neo) adjuvant setting"Подробнее

Optimal neoadjuvant and adjuvant therapy for patients with early TNBCПодробнее

KEYNOTE-522 studyПодробнее

TNBC Current and Emerging Therapeutic Strategies | 2023 Best of Breast ConferenceПодробнее

The 2022 OncoAlert Colloquium DAY 1: Breast CancerПодробнее

A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 studyПодробнее

Treatment Planning for Triple Negative Breast Cancer | 2022 Evolution ConferenceПодробнее

abc Oncology Educational Course 2022 - Breast Cancer ModuleПодробнее

Expanding the Benefits of PARP Inhibitors to More Patients With Breast Cancer and Earlier SettingsПодробнее

Breast Cancer Case-Based Panel Discussion | 2022 Midwest Women's Cancer ConferenceПодробнее

Drs. Kuerer, Gradishar & McArthur discuss #breastcancer from #ASBrS22 - https://bit.ly/3JOwU1gПодробнее